Pursuant to Clause 4, Article 14 of Circular No. 96/2020/TT-BTC dated November 16, 2020, issued by the Minister of Finance on guidelines for information disclosure on the securities market, Hai Duong Pharmaceutinal and Medical Materials Joint Stock Company hereby provides justifications regarding the Quarter IV/2024 Financial Report as follows:
See document details, here.
HDPHARMA
CONTACT US
VN
EN